Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Seelos Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
SEEL
Nasdaq
8731
https://seelostherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Seelos Therapeutics Inc
UPDATE 2-Seelos Therapeutics' ALS treatment fails mid-stage study
- Mar 19th, 2024 12:43 pm
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose)
- Mar 19th, 2024 12:15 pm
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Jan 26th, 2024 1:30 pm
Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002
- Jan 22nd, 2024 1:00 pm
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
- Jan 9th, 2024 6:56 pm
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
- Jan 2nd, 2024 1:00 pm
11 Best Psychedelic Stocks to Buy in 2024
- Dec 29th, 2023 1:47 pm
Seelos Therapeutics, Inc. Releases Letter to its Stockholders
- Dec 22nd, 2023 1:00 pm
11 Most Promising Psychedelic Stocks According to Hedge Funds
- Dec 20th, 2023 7:15 pm
Insider Spends US$100k Buying More Shares In Seelos Therapeutics
- Dec 4th, 2023 10:02 am
Insider Buying: CFO Michael Golembiewski Acquires 83,000 Shares of Seelos Therapeutics Inc (SEEL)
- Dec 2nd, 2023 10:05 am
Seelos Therapeutics Announces Closing of Public Offering
- Dec 1st, 2023 9:00 pm
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
- Nov 29th, 2023 2:26 am
Seelos Therapeutics Announces Proposed Public Offering
- Nov 28th, 2023 9:00 pm
Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)
- Nov 27th, 2023 1:00 pm
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
- Nov 24th, 2023 3:53 pm
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
- Oct 27th, 2023 12:11 pm
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
- Oct 17th, 2023 12:00 pm
Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease
- Sep 27th, 2023 12:00 pm
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- Sep 25th, 2023 11:00 am
Scroll